Radiopharmaceutical developer Navidea Biopharmaceuticals said that interim analysis of an ongoing phase IIB study shows positive results from using its technetium-99m tilmanocept radiopharmaceutical in patients with rheumatoid arthritis (RA).
The analysis showed that tilmanocept planar imaging could provide quantitative imaging in both healthy controls and patients with RA, according to the vendor. Furthermore, the technique was stable, reproducible, and can define joints with and without RA-involved inflammation, Navidea said.
The company said it's continuing to enroll patients to complete the phase IIB trial and prepare for the upcoming phase III trial.
